
Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation

In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.

Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.
Dr. Dhandapani Ashok discusses patient and caregiver burden in pediatric EoE and the challenges with identifying EoE in a young patient population.
Experts from different specialties use a case-based discussion to understand type 2 inflammatory diseases from a nurse practitioner perspective.

Presentation highlights from the ADVENT symposium at the EAACI 2023 congress in Hamburg, Germany.

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.

Watch highlights from the AAAAI 2023 Conference in San Antonio, TX, USA.
Experts Prof. Ingrid Terreehorst and Prof. Arjan Bredenoord discuss the allergist’s perspective on identifying and management of patients with EoE.
Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.
Dr. Seema Aceves discusses the role of type 2 inflammation in EoE pathophysiology and disease burden.